SIC
TERN

Salem Investment Counselors’s Terns Pharmaceuticals TERN Stock Holding History

Salem Investment Counselors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-346,850
Closed -$2.6M – 1063
2025
Q3 		$2.6M Hold
346,850
– – 0.07% 137
2025
Q2 		$1.29M Hold
346,850
– – 0.04% 180
2025
Q1 		$957K Buy
346,850
+125
+0% +$510 0.03% 193
2024
Q4 		$1.92M Sell
346,725
-29,875
-8% -$202K 0.06% 152
2024
Q3 		$3.14M Buy
376,600
+5,000
+1% +$41.1K 0.09% 116
2024
Q2 		$2.53M Buy
+371,600
New +$2.25M 0.08% 130

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

Salem Investment Counselors's TERN Position: Q4 2025 in Review

Salem Investment Counselors sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 346,850 shares — an estimated $2.6M sold.

Salem Investment Counselors first reported a position in TERN in Q2 2024 and held it in 6 quarters. The position peaked at $3.14M in Q3 2024. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

  • Salem Investment Counselors reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Salem Investment Counselors sold 346,850 Terns Pharmaceuticals shares in Q4 2025, an estimated $2.6M.
  • Salem Investment Counselors first reported a position in Terns Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • Salem Investment Counselors's Terns Pharmaceuticals position peaked at $3.14M in Q3 2024.
  • 248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on Salem Investment Counselors's 13F filing for Q4 2025, filed 12 Jan 2026.